The U.S. Food and Drug Administration (FDA) had many approvals this week including a treatment created by GlaxSmithKline for Lupus Nephritis in adults, one of the most common autoimmune diseases. The FDA approval for GlaxoSmithKline was historic, as Benlysta is the first medicine approved to treat both systemic lupus and lupus nephritis. Among additional FDA approvals were MacroGenics Inc.’s breast cancer treatment, Athenex Inc.’s premier treatment for actinic keratosis, and Genetech Inc.’s improved version of their own multiple sclerosis drug Ocrevus.

Read more here.  

More on: